Pfizer to buy Biohaven Pharmaceutical for $11.6 billion
Pfizer said it will buy migraine drug maker Biohaven Pharmaceutical Holding Company for about $11.6 billion in cash, as the drugmaker seeks to beef up its portfolio ahead of patent losses for some cancer drugs.
Business
• 10 May 22
